Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Clinical Trials in China

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University481 Fudan University478 Second Affiliated Hospital, Zhejiang University, School of Medicine401 Ruijin Hospital289 Peking Union Medical College Hospital279
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials in this register

19187 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
RenJi Hospital
Not applicable
1,200
Nanjing, Nanchang, Jinan, Shanghai, Xi’an, Tianjin, Hangzhou
2023-12-27
Recruiting
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 2
20
Zhuhai
2023-12-27
By invitation
Fujian Medical University Union Hospital
Phase 2
35
Fuzhou
2023-12-26
Recruiting
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1/2
110
Beijing, Hangzhou, Jinan, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an
2023-12-26
By invitation
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM
NCT06616727Recurrent Glioblastoma Multiforme (GBM)
Shanghai Simnova Biotechnology Co.,Ltd.
Phase 1
50
Beijing
2023-12-26
Recruiting
Hinova Pharmaceuticals Inc.
Phase 1/2
84
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Guiyang, Zhengzhou
2023-12-26
Recruiting
Fujian Akeylink Biotechnology Co., Ltd.
Phase 2
45
Beijing
2023-12-26
Recruiting
Henan Provincial People's Hospital
Observational
400
Zhengzhou
2023-12-26
Recruiting
Sun Yat-sen University
Phase 3
200
Guangzhou
2023-12-26
Recruiting
Hunan Province Tumor Hospital
Phase 1/2
430
Changsha
2023-12-25
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
240
Guangzhou
2023-12-25
Active, closed
Study of Human Bone Marrow Mesenchymal Stem Cells in APAP
NCT06111846Autoimmune Pulmonary Alveolar Proteinosis
Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
Phase 2
10
Beijing
2023-12-25
Recruiting
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
NCT06177041Locally Advanced Unresectable or Metastatic Gastric Cancer, Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsCapecitabine·Oxaliplatin
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 3
486
Beijing
2023-12-25
Recruiting
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Phase 1/2
30
Shenzhen
2023-12-25
Recruiting
Yunnan Cancer Hospital
Not applicable
120
Kunming
2023-12-25
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 3
270
Bengbu, Bozhou, Hefei, Beijing, Fuzhou, Dalian, Shanghai, Changzhi
2023-12-25
Recruiting
Wuhan High Myopia Study
NCT06162234High Myopia
Renmin Hospital of Wuhan University
Observational
1,000
Wuhan
2023-12-25
Recruiting
Xuzhou Medical University
Phase 1/2
20
Xuzhou
2023-12-25
Recruiting
Shengjing Hospital
Observational
50
Shenyang
2023-12-24
Recruiting
RenJi Hospital
Not applicable
120
Shanghai
2023-12-24
Recruiting
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)
NCT05872685Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair
DrugsSerplulimab·Oxaliplatin
Yu jiren
Phase 2
314
Hangzhou, Lishui, Ningbo, Taizhou
2023-12-24
Recruiting
Yunnan Cancer Hospital
Not applicable
129
Kunming
2023-12-23
Recruiting
First Affiliated Hospital of Fujian Medical University
Phase 1
35
Fuzhou
2023-12-23
Active, closed
nthalmic Pty Ltd
Not applicable
210
Tianjin, Shanghai
2023-12-22
Active, closed
Beijing Chest Hospital
Phase 3
186
Beijing, Changsha, Hefei, Jiamusi, Shandong, Xi'an, Xinxiang, Shijiazhuang
2023-12-22
Recruiting
Bivision Pharmaceuticals, Inc.
Phase 1/2
90
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Wuxi
2023-12-22
Recruiting
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Phase 3
1,584
Nanning
2023-12-21
Active, closed
Bristol-Myers Squibb
Phase 3
190
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-12-21
Active, closed
Fudan University
Not applicable
50
Shanghai
2023-12-21
Recruiting
Eli Lilly and Company
Phase 3
1,264
Beijing, Changchun, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou
2023-12-21
Active, closed
AstraZeneca
Observational
409
Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Nanning, Guiyang, Shijiazhuang
2023-12-20
Recruiting
Harbin Medical University
Not applicable
90
Harbin
2023-12-20
Recruiting
Ascentage Pharma Group Inc.
Phase 3
400
Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Nanning, Zhengzhou, Wuhan
2023-12-20
Active, closed
Suzhou Alphamab Co., Ltd.
Phase 2
241
Shanghai
2023-12-20
Recruiting
Haiyan Wang
Observational
438
Jinan
2023-12-20
Recruiting
Ruijin Hospital
Early Phase 1
34
Shanghai
2023-12-20
Recruiting
Tavotek Biotherapeutics
Phase 1
50
Chongqing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Jinan
2023-12-20
Recruiting
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
108
Guangzhou
2023-12-20
Not yet open
ShiCang Yu
Not applicable
20
Chongqing
2023-12-20
Not yet open
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
160
Shanghai
2023-12-20
Recruiting
Li Xiaorong
Early Phase 1
6
Tianjin
2023-12-20
Recruiting
Janssen Research & Development, LLC
Phase 1
300
Beijing, Hangzhou, Tianjin
2023-12-20
Recruiting
Dongguan TT Medical
Not applicable
280
Beijing
2023-12-20
Not yet open
Convalife (Shanghai) Co., Ltd.
Phase 2
98
Beijing
2023-12-20
Recruiting
Shandong Suncadia Medicine Co., Ltd.
Phase 1/2
146
Beijing, Guangzhou
2023-12-20
Recruiting
yue junhan
Phase 2
36
Jinhua
2023-12-20
By invitation
Zhujiang Hospital
Not applicable
220
Guangzhou
2023-12-20
Active, closed
AbbVie
Phase 3
614
Beijing, Guangzhou, Wuhan, Xi'an, Jinan, Shanghai, Chengdu, Tianjin
2023-12-19
Recruiting
Zhongda Hospital
Not applicable
188
Beijing, Nanjing
2023-12-19
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
324
Bengbu, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Dalian
2023-12-19
Recruiting
Fudan University
Observational
168
Guangzhou, Shenyang, Shanghai
2023-12-18
Recruiting
Fudan University
Observational
276
Shanghai
2023-12-18
Recruiting
Shandong First Medical University
Phase 4
1,200
Chongqing, Zhengzhou, Binzhou, Dezhou, Feicheng, Jinan, Liaocheng, Linqing
2023-12-18
Recruiting
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
NCT06014190Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
DrugHS-20089
Hansoh BioMedical R&D Company
Phase 2
460
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang
2023-12-18
Recruiting
Hansoh BioMedical R&D Company
Phase 2
170
Hefei, Beijing, Fuzhou, Guangzhou, Zhuhai, Nanning, Harbin, Zhengzhou
2023-12-18
Recruiting
Peking Union Medical College Hospital
Not applicable
102
Beijing
2023-12-18
Active, closed
Fudan University
Phase 2
20
Shanghai
2023-12-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Wuhan, Changsha, Nanjing
2023-12-18
Recruiting
The Second Hospital of Nanjing Medical University
Observational
100
Nanjing
2023-12-17
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Observational
2,000
Shanghai
2023-12-16
Recruiting
Peking Union Medical College Hospital
Observational
33
Beijing
2023-12-15
Recruiting
Shanghai Chest Hospital
Observational
200
Shanghai
2023-12-15
Recruiting
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
NCT06255223Renal Cell Carcinoma, Radiotherapy, Immune Checkpoint Inhibitor
Jinling Hospital, China
Phase 2
35
Nanjing
2023-12-15
Recruiting
A Study of YL202 in Selected Patients With Advanced Solid Tumors
NCT06107686NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
DrugYL202 should be infused
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shantou, Guilin
2023-12-15
Not yet open
Two Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity
NCT06137352HPV Infection, HPV Vaccine, Cervical Cancer Prevention
Fujian Maternity and Child Health Hospital
Observational
3,000
Fuzhou
2023-12-15
Not yet open
Fudan University
Phase 2
182
Shanghai
2023-12-15
Recruiting
Peking University Third Hospital
Not applicable
50
Beijing
2023-12-15
Recruiting
Westlake University
Phase 1
80
Shaoxing
2023-12-15
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Shijiazhuang, Harbin
2023-12-15
Recruiting
Shanghai Jiao Tong University School of Medicine
Observational
2,042
Shanghai
2023-12-15
Recruiting
AstraZeneca
Phase 3
1,145
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongwan, Fuzhou
2023-12-14
Recruiting
ALI/ARDS Clinical Sub-phenotyping Study
NCT06123962Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
China-Japan Friendship Hospital
Observational
1,500
Beijing
2023-12-14
Active, closed
Shenzhen TargetRx Co., Ltd.
Phase 3
321
Guangzhou
2023-12-14
Recruiting
Sun Yat-sen University
Phase 2
60
Guangzhou
2023-12-14
Recruiting
National Health Research Institutes, Taiwan
Observational
300
2023-12-13
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
DrugsL-leucovorin·Nanoliposomal Irinotecan·Onivyde·Sonesitatug Vedotin
AstraZeneca
Phase 2
226
Changsha, Chengdu
2023-12-13
Recruiting
Yang Li
Phase 2
50
Guangzhou
2023-12-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Hefei, Beijing, Chongqing, Guangzhou, Liuzhou, Nanning, Guiyang, Haikou
2023-12-13
Active, closed
Sanofi
Phase 3
1,655
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou
2023-12-13
Recruiting
Bio-Thera Solutions
Phase 2/3
526
Wuhan
2023-12-13
Active, closed
Deciphera Pharmaceuticals, LLC
Phase 3
54
2023-12-13
Active, closed
Xuanwu Hospital, Beijing
Not applicable
38
Beijing
2023-12-12
Recruiting
Shanghai Refreshgene Technology Co., Ltd.
Phase 1/2
48
Tianjin
2023-12-12
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
92
Guangzhou, Nanning, Cangzhou, Chengde, Tangshan, Xingtai, Harbin, Zhengzhou
2023-12-12
Recruiting
HTA Co., Ltd.
Phase 3
184
Beijing
2023-12-12
Recruiting
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
3,000
Guangzhou
2023-12-12
Recruiting
HighField Biopharmaceuticals Corporation
Phase 1
84
Guangzhou
2023-12-12
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
58
Shanghai
2023-12-12
Active, closed
Lynk Pharmaceuticals Co., Ltd
Phase 3
430
Beijing
2023-12-12
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
52
Shanghai
2023-12-11
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
500
Guangzhou
2023-12-11
Recruiting
Shanghai Tongji Hospital, Tongji University School of Medicine
Early Phase 1
12
Shanghai
2023-12-11
Active, closed
Hoffmann-La Roche
Phase 3
1,050
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2023-12-11
Recruiting
Eikon Therapeutics
Phase 1/2
156
Guangzhou, Shijiazhuang, Jinan, Hangzhou, Chongqing, Fuzhou, Shanghai
2023-12-11
Recruiting
Tianjin Chest Hospital
Not applicable
800
Beijing, Lanfang, Tianjin
2023-12-11
Recruiting
Chinese Occupational Population Cohort of Lifestyle and Physical Fitness (LiFitChina)
NCT06275009Lifestyle, Physical Fitness, Cardiovascular Diseases
China National Center for Cardiovascular Diseases
Observational
18,512
Beijing
2023-12-11
Active, closed
Syndax Pharmaceuticals
Phase 2
145
2023-12-11
Recruiting
AbbVie
Phase 3
110
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2023-12-11
Recruiting
Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC
NCT06177015Metastatic Prostate Cancer, Intermitent Anti-androgen Therapy
DrugDarolutamide
The First Affiliated Hospital with Nanjing Medical University
Phase 3
200
Nanjing
2023-12-11
Recruiting
Cell Energy Life Sciences Group Co. LTD
Phase 1/2
150
Beijing, Shenzhen, Shijiazhuang
2023-12-10
Recruiting
West China Hospital
Not applicable
100
Chengdu
2023-12-10
By invitation
Affiliated Hospital of Nantong University
Observational
300
Nantong
2023-12-10
Recruiting
Peking Union Medical College Hospital
Not applicable
1,224
Beijing
2023-12-08
Recruiting
Zhejiang ACEA Pharmaceutical Co. Ltd.
Phase 1
84
Hangzhou
2023-12-08
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
178
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Luoyang
2023-12-08
Recruiting
Sun Yat-sen University
Phase 2
25
Guangzhou
2023-12-07
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Fuzhou, Guangzhou, Changsha, Wuxi, Changchun, Jinan, Chengdu, Ürümqi
2023-12-07
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
88
Chongqing, Xi'an
2023-12-07
Recruiting
Jian Chen
Phase 2
77
Shanghai
2023-12-07
Recruiting
Emotion Regulation Dysfunctions in NSSI Adolescents in Naturalistic Contexts
NCT05907421Nonsuicidal Self Injury, Emotion Regulation
University of Electronic Science and Technology of China
Observational
80
Chengdu
2023-12-06
Recruiting
Social Feedback and Dysfunctional Risk Taking in NSSI Adolescents
NCT05981677Nonsuicidal Self Injury, Risk-Taking
University of Electronic Science and Technology of China
Observational
80
Chengdu
2023-12-06
Recruiting
Changchun Intellicrown Pharmaceutical Co. LTD
Phase 1
138
Changchun
2023-12-06
Recruiting
Organoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer
NCT06155305Organoids, Breast Cancer, Neoadjuvant Chemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
58
Hangzhou
2023-12-06
Recruiting
Impact of Emotional Reactivity on Dysfunctional Decision-Making in NSSI Adolescents
NCT05981612Nonsuicidal Self Injury, Prediction Errors
University of Electronic Science and Technology of China
Observational
80
Chengdu
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang, Nanning
2023-12-06
Recruiting
Ruijin Hospital
Not applicable
89
Shanghai
2023-12-06
Recruiting
Altered Neural Pain Empathic Reactivity in NSSI Adolescents
NCT05968313Nonsuicidal Self Injury, Pain Empathy
University of Electronic Science and Technology of China
Observational
80
Chengdu
2023-12-06
Not yet open
BioSyngen Pte Ltd
Early Phase 1
6
Shenzhen
2023-12-05
Recruiting
AstraZeneca
Phase 1/2
226
Beijing, Changsha, Guangzhou, Shenyang
2023-12-05
Recruiting
Fudan University
Phase 2
65
Shanghai
2023-12-05
Recruiting
Chinese SLE Treatment And Research Group
Observational
100
Beijing
2023-12-05
Recruiting
First Affiliated Hospital of Zhejiang University
Observational
100
Hangzhou
2023-12-04
Active, closed
AstraZeneca
Phase 3
760
Beijing, Changchun, Changsha, Chengdu, Deyang, Fuzhou, Guangzhou, Guiyang
2023-12-04
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
386
Guangzhou
2023-12-04
Recruiting
Jinzhou Medical University
Not applicable
80
Zhengzhou
2023-12-03
Recruiting
Beijing Hospital
Phase 2
296
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Hohhot, Shenyang
2023-12-02
Active, closed
Qilu Hospital of Shandong University
Not applicable
105
Jinan
2023-12-02
Active, closed
Tongji Hospital
Observational
100
Wuhan
2023-12-01
Recruiting
Shanghai Zhongshan Hospital
Phase 2
26
Shanghai
2023-12-01
Recruiting
First Affiliated Hospital of Zhejiang University
Observational
210
Hangzhou
2023-12-01
Recruiting
Chinese University of Hong Kong
Not applicable
81
Guangzhou
2023-12-01
Not yet open
Gang Wu
Not applicable
70
Zhengzhou
2023-12-01
Recruiting
Chinese University of Hong Kong
Not applicable
1,016
Hong Kong
2023-12-01
Recruiting
An Exploratory Study of Focal Pulse Ablation System in the Treatment of Atrial Arrhythmia
NCT06157437Typical Atrial Flutter, Atrial Fibrillation (AF)
Hangzhou Dinova EP Technology Co., Ltd
Not applicable
10
Beijing
2023-12-01
Active, closed
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation
NCT05975307Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy
DrugsJS001·Toripalimab·Gemcitabine·Cisplatin
Sun Yat-sen University
Phase 2
64
Guangzhou
2023-12-01
Recruiting
Hubei Cancer Hospital
Not applicable
98
Wuhan
2023-12-01
Recruiting
Xinqiao Hospital of Chongqing
Not applicable
100
Xiangtan
2023-12-01
Recruiting
Jiawei Jiang
Not applicable
100
Nantong
2023-12-01
By invitation
Shanghai Jiao Tong University School of Medicine
Observational
1,000
Shanghai
2023-12-01
Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.
Not applicable
290
Beijing, Chongqing, Changsha, Nanjing, Suzhou, Shanghai, Xi’an, Chengdu
2023-12-01
Active, closed
Can a Smartphone Listen to Your Heart? A Performance Study on Detecting Abnormalities in Your Heart Sounds
NCT06070298Valvular Heart Disease, Heart Murmurs, Cardiovascular Abnormalities
Wong Chun Ka
Observational
577
Hong Kong
2023-12-01
Recruiting
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency
NCT06095141Pancreatic Adenocarcinoma, Homologous Recombination Deficiency
DrugCisplatin
Fudan University
Phase 2/3
30
Shanghai
2023-12-01
Recruiting
Smartphone-based Remote Symptom Monitoring to Improve Postoperative Rehabilitation Exercise Adherence After Video-assisted Thoracic Surgery (VATS) for Lung Cancer
NCT05990946Lung Neoplasms, Non-Small Cell Lung Cancer, Postoperative Complications, Patient Reported Outcome Measures, Telerehabilitation
Zhongshan People's Hospital, Guangdong, China
Not applicable
736
Zhongshan
2023-12-01
Recruiting
Shanghai Mental Health Center
Not applicable
138
Shanghai
2023-12-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
60
Tianjin
2023-12-01
Recruiting
NV-001 in the Treatment of Advanced Solid Tumors
NCT06051760Malignant Neoplasm
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
20
Beijing
2023-12-01
Active, closed
Min-Tze LIONG
Phase 2
60
Jiading
2023-12-01
Not yet open
Wen-hong Zhang
Observational
5,000
Hefei, Fuzhou, Wuhan, Nanjing, Xuzhou, Jinan, Taiyuan, Xi’an
2023-12-01
Not yet open
Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement
NCT06131489Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus, Bowel Resection
Beijing Friendship Hospital
Observational
20
Beijing
2023-12-01
Not yet open
Efficacy and Safety of Immunosuppressive Withdrawal After Pediatric Liver Transplantation
NCT06147375Immune Tolerance, Immunosuppression, Liver Transplant; Complications
DrugsCyclosporine A·Tacrolimus
Wei Gao
Not applicable
47
Tianjin
2023-12-01
Not yet open
Shuangyue Liu
Phase 2
178
Chengdu
2023-12-01
Active, closed
Shandong Cancer Hospital and Institute
Phase 3
128
Jinan
2023-12-01
Recruiting
Incremental Value of Delayed 68Ga-DOTATATE PET/MR in the Detection of Liver Metastases
NCT07898904Gastroenteropancreatic Neuroendocrine Tumors
First Affiliated Hospital of Fujian Medical University
Observational
46
Fuzhou
2023-12-01
Not yet open
RenJi Hospital
Not applicable
60
Shanghai
2023-12-01
By invitation
Beijing Ditan Hospital
Not applicable
180
Beijing
2023-12-01
By invitation
Avistone Biotechnology Co., Ltd.
Phase 3
327
Guangzhou
2023-12-01
Recruiting
Biometric Changes After Intervention of Anterior Chamber Angle : an Observational Study
NCT06492538Angle-closure Glaucoma, Minimally Invasive Glaucoma Surgery, Goniosynechialysis, Goniotomy
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
300
Guangzhou
2023-12-01
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Observational
250
Shanghai
2023-12-01
Recruiting
An Observational Study of Menopausal Symptom in Patients With Gynecological Malignancy After Oophorectomy
NCT06151028Gynecological Malignancies, Menopausal Symptoms, Bone Loss
Anhui Provincial Hospital
Observational
490
Hefei
2023-12-01
Not yet open
Jing Huang
Not applicable
200
Chongqing
2023-12-01
Recruiting
Third Affiliated Hospital, Sun Yat-Sen University
Observational
80
Guangzhou
2023-12-01
Recruiting
Changzhou No.2 People's Hospital
Not applicable
300
Changzhou
2023-12-01
Active, closed
AstraZeneca
Phase 3
64
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Ha’erbin, Jinan
2023-12-01
Recruiting
Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women
NCT06417736Endometrial Cancer Stage I, Endometrial Hyperplasia
DrugMegestrol Acetate
Women's Hospital School Of Medicine Zhejiang University
Not applicable
75
Hangzhou
2023-12-01
Recruiting
Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC
NCT06170710Head and Neck Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
173
Beijing
2023-12-01
Active, closed
Feng Gao
Observational
144
Wuhan
2023-12-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1/2
150
Hangzhou
2023-12-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
1,384
Beijing, Shanghai, Chengdu
2023-12-01
Recruiting
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
260
Shanghai
2023-12-01
Active, closed
Rapid Abdominal Diagnosis With AI & Radiology
NCT07040358Abdominal Diseases
First Affiliated Hospital of Zhejiang University
Observational
2,000,000
Hangzhou
2023-12-01
Recruiting
Fudan University
Phase 3
266
Shanghai
2023-12-01
Not yet open
RenJi Hospital
Observational
40
Shanghai
2023-12-01
Recruiting
A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
NCT06783816Acute Lymphocytic Leukemia, Lymphoma,Non-Hodgkin, Relapsed Refractory Multiple Myeloma
Shanxi Bethune Hospital
Not applicable
45
Taiyuan
2023-12-01
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 2
50
Nanjing
2023-12-01
Active, closed
Analysis of Clinical Application of China's First Batch of TYRX Absorbable Antibacterial Envelope
NCT06710873CIED Infection, TYRX Absorbable Antibacterial Envelope
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
50
Guangzhou
2023-12-01
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai
2023-12-01
Recruiting
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3
400
Guangzhou, Shanghai, Anyang, Baoding, Beijing, Changchun, Changde, Changsha
2023-12-01
Recruiting
Development and Validation of a Postoperative Re-fracture Risk Model for Osteoporotic Spinal Fractures
NCT06379243Osteoporosis Fracture, Osteoporosis Vertebral, Compression Fracture, Perform PVP / PKP Treatment
The Seventh Affiliated Hospital of Sun Yat-sen University
Not applicable
560
Guangzhou
2023-12-01
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 3
120
Shanghai
2023-12-01
Recruiting
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
NCT06799637Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer, Cervical Cancers
DrugXNW28012
Evopoint Biosciences Inc.
Phase 1/2
350
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guiyang, Baoding, Harbin
2023-12-01
Recruiting
Cancer of Esophagogastric Junction: Optimized Sweet Versus Ivor-Lewis
NCT06162767Esophagogastric Junction Carcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
240
Nanjing
2023-12-01
Not yet open
A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy
NCT06101966Cervical Cancer, Radiotherapy, Distant Metastasis, Prognostic Model
Fujian Cancer Hospital
Observational
500
Fuzhou
2023-12-01
Recruiting
EACH-ADHF: Early Comprehensive Rehabilitation in Patients With ADHF
NCT06161987Acute Decompensated Heart Failure
Guangdong Provincial People's Hospital
Not applicable
140
Guangzhou
2023-12-01
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
45
Wuhan
2023-12-01
By invitation
Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)
NCT06643858Healthy, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Neurodegenerative Diseases
Beijing Tiantan Hospital
Observational
10,000
Beijing
2023-12-01
Not yet open
A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.
NCT06142617Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation
DrugsOsimertinib·Pemetrexed·Keytruda
Peking Union Medical College Hospital
Phase 2
37
Beijing
2023-12-01
Not yet open
Shanghai Chest Hospital
Phase 2
36
Shanghai
2023-12
Not yet open
Huashan Hospital
Early Phase 1
6
Shanghai
2023-12
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2023-12
Not yet open
YiHui Guan
Not applicable
15
Shanghai
2023-12
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
80
Wuhan
2023-12
Not yet open
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2
129
Jinan, Tianjin
2023-12
Recruiting
Ruijin Hospital
Phase 2
30
Beijing, Guangzhou, Henan, Shanghai, Wuhan
2023-11-30
Active, closed
Endovascular Treatment of Cerebrovascular Diseases Guided by Optical Coherence Tomography (OCT) Technology（CVD-OCT）
NCT06986330Carotid Stenosis, Optical Coherence Tomography (OCT), Endovascular Treatment
First Affiliated Hospital of Wannan Medical College
Observational
200
Wuhu
2023-11-30
Recruiting
West China Hospital
Phase 2
17
Chengdu
2023-11-30
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
366
Beijing
2023-11-30
Recruiting
Cohort of Nursing Homes
NCT07249086Health Status
Institute of Hematology & Blood Diseases Hospital, China
Observational
1,500
Tianjin
2023-11-30
Not yet open
Zhejiang Cancer Hospital
Phase 1/2
58
Hangzhou
2023-11-30
By invitation
Xiaomeng Zheng
Observational
40
Fuzhou
2023-11-29
Active, closed
argenx
Observational
413
Changsha, Nanchang, Shanghai
2023-11-29
Recruiting
Liu Huang
Phase 2
25
Wuhan
2023-11-28
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
170
Shanghai
2023-11-28
Recruiting
RemeGen Co., Ltd.
Phase 2
40
Shanghai
2023-11-28
Recruiting
The Children's Hospital of Zhejiang University School of Medicine
Phase 3
20
Hangzhou
2023-11-28
Recruiting
Peking University
Phase 2
54
Beijing
2023-11-28
Active, closed
Chronic Kidney Disease Registry Platform Study
NCT06117852Chronic Kidney Diseases
AstraZeneca
Observational
5,000
Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Dongguan, Guangzhou
2023-11-28
By invitation
Shanghai Zhongshan Hospital
Observational
28
Shanghai
2023-11-28
Recruiting
Renmin Hospital of Wuhan University
Observational
4,000
Wuhan
2023-11-28
Recruiting
Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
NCT05737303Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV, Fallopian Tube Carcinoma Stage III, Fallopian Tube Carcinoma Stage IV
DrugsNab-paclitaxel·Carboplatin
Women's Hospital School Of Medicine Zhejiang University
Phase 3
538
Guangzhou, Ji'nan, Hangzhou, Ningbo, Wenzhou
2023-11-27
Recruiting
Zhejiang Doer Biologics Co., Ltd.
Phase 1
216
Shanghai
2023-11-27
By invitation
Second Affiliated Hospital of Wenzhou Medical University
Observational
1,000
Wenzhou
2023-11-27
Recruiting
RemeGen Co., Ltd.
Phase 2
90
Beijing, Fuzhou, Kunming, Xiamen, Wuwei, Guangzhou, Harbin, Zhengzhou
2023-11-27
Active, closed
Bayer
Observational
300
Multiple Locations
2023-11-27
Recruiting
Southeast University, China
Not applicable
404
Hefei, Jinjiang, Huai'an, Lianyungang, Nanjing, Nantong, Suzhou, Taizhou
2023-11-27
Recruiting
Huashan Hospital
Observational
160
Shanghai
2023-11-26
Recruiting
Yi Yang
Not applicable
500
Changchun
2023-11-25
Recruiting
NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI
NCT05638867Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome
DrugsRivaroxaban·Clopidogrel·Aspirin
China National Center for Cardiovascular Diseases
Phase 4
3,944
Beijing
2023-11-25
Recruiting
Tang-Du Hospital
Phase 2
100
Xi'an
2023-11-24
By invitation
Shanghai Henlius Biotech
Phase 1
367
Beijing, Changsha
2023-11-24
Recruiting
The Third Affiliated hospital of Zhejiang Chinese Medical University
Not applicable
84
Hangzhou
2023-11-23
Recruiting
Prognosis of Patients With Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy
NCT06204406Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy
RenJi Hospital
Observational
106
Shanghai
2023-11-23
Recruiting
AstraZeneca
Phase 3
625
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2023-11-23
Recruiting
Stomatological Hospital Affiliated with Fujian Medical University
Not applicable
30
Fuzhou
2023-11-23
Recruiting
West China Second University Hospital
Observational
22
Chengdu
2023-11-23
Recruiting
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
NCT06151080DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma
DrugsG-Chop·Lenalidomide
The First Affiliated Hospital of Xiamen University
Phase 2
38
Xiamen
2023-11-22
Recruiting
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
NCT06151106Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma
DrugChidamide
The First Affiliated Hospital of Xiamen University
Phase 2
33
Xiamen
2023-11-22
Recruiting
AZA Combined With RCHOP in P53-mutated DLBCL.
NCT06158399DLBCL - Diffuse Large B Cell Lymphoma, TP53
DrugsR-Chop·Azacitidine
The First Affiliated Hospital of Xiamen University
Phase 2
52
Xiamen
2023-11-22
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 4
50
Tianjin
2023-11-22
Recruiting
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
NCT06158386Follicular Lymphoma, Refractory B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
DrugsLinperlisib·Chidamide
The First Affiliated Hospital of Xiamen University
Phase 2
33
Xiamen
2023-11-22
Recruiting
The First Affiliated Hospital of Xiamen University
Observational
90
Xiamen
2023-11-22
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
25
Xiamen
2023-11-22
Recruiting
Safety and Efficacy of Remote Ischemic Conditioning for Patients Taking Off-pump Coronary Artery Bypass Grafting
NCT06141525Coronary Artery Bypass Grafting, Remote Ischemic Conditioning, Ischemia-Reperfusion Injury
First Affiliated Hospital Xi'an Jiaotong University
Not applicable
648
Xi'an
2023-11-22
Active, closed
Guangzhou Preterm and Term Birth Cohort Study
NCT07756177Preterm Birth, Neurodevelopmental Disorders, Overweight, Obesity
Sun Yat-sen University
Observational
200
Guangzhou
2023-11-21
Recruiting
Henan Cancer Hospital
Phase 1
20
Zhengzhou
2023-11-21
Active, closed
AstraZeneca
Phase 3
1,898
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Guilin
2023-11-21
Recruiting
First Affiliated Hospital of Zhejiang University
Observational
57
Hangzhou
2023-11-21
Recruiting
Fudan University
Not applicable
58
Shanghai
2023-11-20
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
100
Wuhan
2023-11-20
Recruiting
Zhujiang Hospital
Observational
255
Foshan, Guangzhou, Shaoguan
2023-11-20
Active, closed
West China Hospital
Phase 1/2
9
Chengdu
2023-11-20
Recruiting
Zhengzhou Yuan
Observational
3,000
Luzhou
2023-11-20
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
DrugsLeucovorin·Adrucil·Oxaliplatin·Bevacizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
914
Guangzhou, Jinan, Shanghai
2023-11-20
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
1,615
Shanghai, Tianjin
2023-11-20
Recruiting
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 1
60
Shanghai
2023-11-20
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
304
Shanghai, Zhejiang
2023-11-20
Active, closed
TransThera Sciences (Nanjing), Inc.
Phase 2
50
Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou
2023-11-17
Recruiting
3D Medicines (Sichuan) Co., Ltd.
Phase 3
390
Tianjin
2023-11-17
Recruiting
Second Affiliated Hospital of Soochow University
Observational
300
Suzhou
2023-11-17
Recruiting
West China Hospital
Early Phase 1
12
Chengdu
2023-11-17
Active, closed
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
NCT05808608Renal Cell Carcinoma, First-line Treatment, Non Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
DrugsAxitinib·Cadonilimab
Hao Zeng
Phase 1/2
37
Chengdu
2023-11-17
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 2
1,163
Nanjing
2023-11-17
Recruiting
Amgen
Phase 3
750
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2023-11-16
Recruiting
He Huang
Early Phase 1
18
Hangzhou
2023-11-16
Recruiting
Tasly Pharmaceutical Group Co., Ltd
Phase 3
480
Beijing, Changsha, Chengdu, Haerbin, Huizhou, Kaifeng, Luoyang, Luzhou
2023-11-16
Recruiting
A Registry Study of Intracranial Atherosclerotic Stenosis Treatment by Intracranial Drug-eluting Stenting in China
NCT05692882Intracranial Arteriosclerosis, Stenosis Artery, Drug-Eluting Stents, Intracranial Artery Stenosis
Sino Medical Sciences Technology Inc.
Not applicable
1,000
Chenzhou, Ganzhou, Jinhua, Ningbo, Shanxi
2023-11-16
Active, closed
Beijing Tiantan Hospital
Not applicable
224
Beijing
2023-11-16
Recruiting
RenJi Hospital
Phase 2
22
Nanjing, Xi'an, Shanghai, Chengdu, Tianjin
2023-11-16
By invitation
Children's Hospital of Fudan University
Observational
1,000
Yiyang, Nantong, Shanghai, Baoji, Quzhou
2023-11-16
Recruiting
Qilu Hospital of Shandong University
Observational
50
Jinan
2023-11-16
Recruiting
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2/3
166
Beijing, Hangzhou
2023-11-16
Recruiting
Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy
NCT06102694Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation
Institute of Hematology & Blood Diseases Hospital, China
Observational
500
Tianjin
2023-11-16
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
376
Beijing
2023-11-16
Recruiting
Ruijin Hospital
Phase 2
23
Shanghai
2023-11-15
Recruiting
Gene Therapy for DME
NCT06492876Diabetic Macular Edema
Frontera Therapeutics
Phase 1/2
78
Tianjin
2023-11-15
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
71
Xiamen
2023-11-15
Recruiting
Qilu Hospital of Shandong University
Observational
6,000
Jinan
2023-11-15
Recruiting
He Huang
Not applicable
3
Hanzhou
2023-11-15
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
756
Harbin, Changsha, Nanchang, Shenyang, Jinan, Anyang, Beijing, Changchun
2023-11-15
Recruiting
Beijing Scitech-Mq Pharmaceuticals Limited
Phase 2
60
Beijing
2023-11-15
Active, closed
AbbVie
Phase 3
289
Chongqing, Xiamen, Guangzhou, Wuhan, Changsha, Changzhou, Nanjing, Wuxi
2023-11-15
Active, closed
AstraZeneca
Phase 3
1,902
Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin
2023-11-14
Not yet open
Akeso
Phase 3
642
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Zhangzhou, Lanzhou
2023-11-14
Active, closed
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
NCT06124378Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
DrugsXeloda·Tislelizumab·Capecitabine·Oxaliplatin
First Affiliated Hospital of Guangxi Medical University
Phase 2
60
Nanning
2023-11-13
Recruiting
Affiliated Hospital of Nantong University
Phase 1/2
30
Nantong
2023-11-13
Recruiting
Xueqin Yang
Observational
44
Chongqing
2023-11-13
Recruiting
Akeso
Phase 2
90
Tianjin
2023-11-13
Recruiting
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 3
162
Beijing, Xiamen, Guangzhou, Shenzhen, Guilin, Shijiazhuang, Xinxiang, Nanchang
2023-11-13
Recruiting
Takeda
Phase 3
80
Beijing, Guangzhou, Shenzhen, Shanghai, Tianjin
2023-11-13
Active, closed
Novartis Pharmaceuticals
Phase 1
28
Shanghai
2023-11-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2023-11-12
Active, closed
BeOne Medicines
Phase 3
652
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Jieyang, Nanning, Nanyang
2023-11-11
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
50
Beijing
2023-11-11
Active, closed
Liaoning Chengda Biotechnology CO., LTD
Phase 4
600
Jiaxing, Jinhua, Ningbo, Quzhou
2023-11-11
Active, closed
First Affiliated Hospital of Chongqing Medical University
Observational
120
Chongqing
2023-11-11
Recruiting
RenJi Hospital
Not applicable
840
Shanghai
2023-11-11
Recruiting
LCMS-Based Metabolic Analysis Explores the Effect of American Ginseng on Urine and Plasma in Healthy Individuals
NCT07252362The Impact of American Ginseng on the Metabolomics of Urine and Plasma in Healthy Individuals
Zhejiang Cancer Hospital
Not applicable
20
Hangzhou
2023-11-11
Recruiting
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
NCT06096909Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome, Lipid Lowering, Vascular Inflammation
DrugTafolecimab
China National Center for Cardiovascular Diseases
Phase 4
3,684
Beijing, Tangshan
2023-11-11
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
100
Changchun
2023-11-10
Recruiting
Xuzhou Medical University
Phase 1/2
20
Xuzhou
2023-11-10
Not yet open
Safety and Efficacy Study of Implantable Neuromodulation for Poststroke Hemiplegia
NCT06121947Stroke Sequelae, Deep Brain Stimulation, Vagus Nerve Stimulation, Motor Recovery
Chinese PLA General Hospital
Not applicable
98
Beijing
2023-11-10
Recruiting
Xuesong Li
Observational
90
Beijing
2023-11-10
Active, closed
China-Japan Friendship Hospital
Observational
12
Beijing
2023-11-10
Recruiting
Comparing Myopia Treatments in Youth: Defocus Spectacles, Glasses, and Ortho-K
NCT06278974Myopia, Cost-effectiveness Analysis, Quality of Life
He Eye Hospital
Observational
90
Shenyang
2023-11-10
Active, closed
AstraZeneca
Phase 3
863
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Kunming, Lanzhou
2023-11-09
Recruiting
Sun Yat-sen University
Phase 2
198
Foshan, Guangzhou, Guiyang
2023-11-09
Active, closed
Evaluate the Safety, Tolerability of BAT6026
NCT06094179Dermatitis, Atopic
Bio-Thera Solutions
Phase 1/2
33
Beijing
2023-11-09
Recruiting
The First Affiliated Hospital of University of Science and Technology of China
Not applicable
18
Changsha
2023-11-09
Recruiting
Zhengzhou Yuan
Observational
8,000
Luzhou
2023-11-09
Recruiting
AbbVie
Phase 1
325
2023-11-09
Active, closed
AstraZeneca
Phase 3
314
Beijing, Guangzhou, Hangzhou, Lanzhou, Shanghai, Tianjin
2023-11-08
Active, closed
Pfizer
Phase 3
1,571
Beijing, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Nanyang, Wuhan, Changsha
2023-11-08
Recruiting
Qishenyiqi Dripping Pill for Coronary Microvascular Disease
NCT06699420Coronary Microvascular Disease
Qilu Hospital of Shandong University
Phase 4
162
Jinan
2023-11-08
Active, closed
A Study of ST-1898 for Unresectable or Metastatic Melanoma
NCT06359860Unresectable or Metastatic Melanoma
DrugST-1898
Beijing Scitech-Mq Pharmaceuticals Limited
Phase 1/2
64
Beijing
2023-11-07
Recruiting
Personalized KSX01-TCRT in Patients With Advanced Solid Tumors
NCT06150365Refractory Solid Tumors, Relapsed Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
12
Beijing
2023-11-07
Recruiting
Second Affiliated Hospital of Soochow University
Not applicable
40
Suzhou
2023-11-07
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2
29
Guangzhou
2023-11-07
Active, closed
Bristol-Myers Squibb
Phase 2
227
Beijing, Guangzhou, Luoyang, Changsha, Hangzhou
2023-11-07
Active, closed
AstraZeneca
Phase 3
1,835
Baotou, Beijing, Changsha, Chengdu, Chongqing, Deyang, Foshan, Guangzhou
2023-11-07
Recruiting
Chongqing Precision Biotech Co., Ltd
Phase 1
60
Wuhu
2023-11-06
By invitation
Second Affiliated Hospital of Nanchang University
Observational
100
Nanchang
2023-11-06
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
130
Beijing
2023-11-06
Recruiting
Catheter Ablation in Atrial Fibrillation Patients With HFpEF (STABLE-SR IV Trial)
NCT06125925Atrial Fibrillation, HFpEF - Heart Failure With Preserved Ejection Fraction
The First Affiliated Hospital with Nanjing Medical University
Not applicable
436
Nanjing
2023-11-06
Recruiting
Lu jin ，MD
Phase 2
10
Shanghai
2023-11-06
By invitation
Clinical Study of Rezvilutamide Combined With Docetaxel Chemotherapy in the Treatment of Abiraterone-Resistant Prostate Cancer
NCT07112209Pathological and Imaging Examinations Confirmed Metastatic Prostate Cancer
Zhujiang Hospital
Not applicable
20
Guangzhou
2023-11-06
Recruiting
Prospective Cohort of Patients With Intracerebral Hemorrhage
NCT06670456Stroke, Acute, Intracerebral Hemorrhage
De-zhi Kang
Observational
3,000
Fuzhou, Quanzhou, Xiamen, Zhangzhou, Liaocheng
2023-11-06
Recruiting
Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence
NCT06078969Langerhans Cell Histiocytosis of Bone
DrugPrednisone
Shanghai Changzheng Hospital
Phase 2
118
Shanghai
2023-11-04
Recruiting
Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
NCT06125652Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
Xuzhou Medical University
Phase 1/2
20
Xuzhou
2023-11-04
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
25
Shanghai
2023-11-04
Active, closed
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
NCT06093841Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma
DrugsRelmacabtagene Autoleucel·Relma-cel·Fludarabine·Cyclophosphamide
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
46
Guangzhou, Zhengzhou, Changsha, Suzhou, Jinan, Shanghai, Tianjin, Hangzhou
2023-11-03
Recruiting
Shanghai Kechow Pharma, Inc.
Phase 3
165
Beijing
2023-11-02
Active, closed
Amgen
Phase 3
633
2023-11-02
Recruiting
Zhejiang University
Early Phase 1
7
Hangzhou
2023-11-02
Recruiting
A Study to Test Tetrandrine Tablets for Connective Tissue Disease-Related Lung Disease
NCT07319598Interstitial Lung Disease (ILD), Connective Tissue Disease-associated Interstitial Lung Disease
Peking University Third Hospital
Phase 4
100
Beijing
2023-11-02
Recruiting
Mianyang Central Hospital
Phase 1/2
20
Mianyang
2023-11-02
Recruiting
Disease Characteristics of IR-CAD: a Case-control Study
NCT06007248Coronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis, Coronary Artery Disease Progression
Peking Union Medical College Hospital
Observational
30
Beijing
2023-11-02
Recruiting
First Hospital of China Medical University
Not applicable
352
Shenyang
2023-11-01
Recruiting
Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers
NCT06139042Liver Cancer, Biliary Tract Cancer, Pancreatic Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,608
Hangzhou
2023-11-01
Recruiting
Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation
NCT06221722Constipation - Functional, Refractory Constipation, Fluoxetine, fMRI
DrugFluoxetine
Xijing Hospital of Digestive Diseases
Observational
150
Yinchuan, Xi'an
2023-11-01
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 2
120
Shanghai
2023-11-01
Active, closed
Heidelberg University
Observational
600
Beijing
2023-11-01
Recruiting
Peking University Third Hospital
Observational
120
Beijing
2023-11-01
Recruiting
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
50
Shanghai
2023-11-01
By invitation
West China Second University Hospital
Observational
100
Chengdu
2023-11-01
By invitation
Chao Ji
Observational
150
Fuzhou
2023-11-01
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
40
Beijing
2023-11-01
Recruiting
Guangzhou 8th People's Hospital
Observational
100
Guangzhou
2023-11-01
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 2
70
Nanjing
2023-11-01
Active, closed
Beijing Tsinghua Chang Gung Hospital
Observational
918
Beijing
2023-11-01
Not yet open
Radial Artery Versus No-touch Saphenous Vein
NCT06014047Coronary Artery Disease
China National Center for Cardiovascular Diseases
Not applicable
774
Beijing
2023-11-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1
24
Guangzhou
2023-11-01
Recruiting
Janssen Research & Development, LLC
Phase 1
355
Chongqing, Wenzhou, Xi'an
2023-11-01
Recruiting
Surveillance for Multifocal GGNs
NCT06097910Lung Ground-glass Opacities, Active Surveillance
Fudan University
Observational
370
Shanghai
2023-11-01
Recruiting
Yun Chen
Observational
178
Nanjing
2023-11-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
160
Hangzhou
2023-11-01
Recruiting
Assessment System of Sarcopenia in Lung Cancer Patients
NCT06327594Sarcopenia, Lung Cancer, Ultrasound
West China Hospital
Observational
1,500
Chengdu
2023-11-01
Recruiting
PPG vs. ICG in Gastrointestinal Resections
NCT06222645Anastomosis, Perfusion, Postoperative Complications, Gastrointestinal Neoplasms
Saint Petersburg State University, Russia
Not applicable
200
Yantai
2023-11-01
Recruiting
TDCS Interventions for Subthreshold Depressive Symptoms in Young Individuals.
NCT06294184Subthreshold Depression, Young People, Transcranial Direct Current Stimulation
Guangzhou Psychiatric Hospital
Not applicable
150
Guangzhou
2023-11-01
Active, closed
Peking University Third Hospital
Not applicable
146
Beijing
2023-11-01
Recruiting
Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program
NCT07270419Aneurysmal Subarachnoid Hemorrhage
Xiaolin Chen, MD
Observational
2,000
Beijing
2023-11-01
Recruiting
Peking University Cancer Hospital & Institute
Phase 2
116
Beijing
2023-11-01
Recruiting
Pan-Amyloid PET/CT in Various Amyloid-Related Disease
NCT07130565Amyloid, Cardiac Amyloidosis, Amyloidosis
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2023-11-01
Active, closed
PET-CT Predicting Lymph Nodes Metastasis
NCT05970913Non Small Cell Lung Cancer, Lymph Node Metastasis, Positron Emission Tomography
Fudan University
Observational
280
Shanghai
2023-11-01
Recruiting
Mao Jianhua
Phase 3
140
Wuhan, Nanjing, Kunming, Hangzhou, Ningbo, Wenzhou, Beijing, Shanghai
2023-11-01
Recruiting
Juan Kang
Observational
300
Chongqing
2023-11-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Observational
500
Tianjin
2023-11-01
Not yet open
Shenzhen Kangning Hospital
Not applicable
150
Shenzhen
2023-11-01
Not yet open
China Medical University, China
Phase 2
30
Shenyang
2023-11-01
Recruiting
Cohort in Qianwan New District, Ningbo
NCT06387875Cardiovascular Diseases, Stroke, Non-Communicable Chronic Diseases
RenJi Hospital
Observational
30,000
Shanghai
2023-11-01
Recruiting
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
NCT05952947Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina, Carcinoma of Penis
DrugsFludarabine·Cyclophosphamide
HRYZ Biotech Co.
Phase 1
32
Shanghai
2023-11-01
Recruiting
Tianjin Huanhu Hospital
Observational
200
Tianjin
2023-11-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1
24
Guangzhou
2023-11-01
Recruiting
Ming-Yuan Chen
Not applicable
86
Guangzhou, Zhuhai
2023-11-01
Recruiting
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
NCT06017284Pancreatic Cancer Stage IV, Chemotherapy-induced Nausea and Vomiting
DrugsThalidomide·Nab-paclitaxel·Gemcitabine
Fudan University
Phase 3
100
Shanghai
2023-11-01
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
334
Guangzhou
2023-11-01
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
868
Nanjing
2023-11-01
Recruiting
Personalized T-Cell Therapy iNeo-Vac-T01 in Advanced Colorectal Cancer
NCT07504523Metastatic Colorectal Cancer (CRC)
Ying Yuan, MD
Phase 1
20
Hangzhou
2023-11-01
Recruiting
Peking Union Medical College Hospital
Phase 2
22
Beijing
2023-11-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
170
Beijing, Guangzhou, Jinan
2023-11-01
Not yet open
Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)
NCT06102161Lung Cancer, Wedge Resection, Ground-glass Opacity
Fudan University
Phase 3
286
Shanghai
2023-11
Recruiting
Nanfang Hospital, Southern Medical University
Not applicable
178
Guangzhou
2023-10-31
Recruiting
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
NCT06041477Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity
Sun Yat-sen University
Phase 3
540
Guangzhou
2023-10-31
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
376
Beijing
2023-10-31
Recruiting
Shanghai Zhongshan Hospital
Not applicable
428
Shanghai
2023-10-31
Recruiting
TaiRx, Inc.
Phase 1
30
2023-10-31
Active, closed
Shouyao Holdings (Beijing) Co. LTD
Phase 3
120
Shanghai
2023-10-31
Active, closed
Observational, Bivariate Analysis of Clinical Big Data in Patients With Cervical Cancer
NCT06480617Progression-free Survival Was Defined From Date of Surgery to Disease Progression Post-surgery or Death or Last Follow-up, Overall Survival Was Defined as Time From Surgery to Death From Any Cause or Last Follow-up
Anhui Provincial Hospital
Observational
3,000
Hefei
2023-10-31
Recruiting
Clinical Value of ETCOc in the Diagnosis and Treatment of ABO-HDN
NCT05842109ABO Hemolytic Disease of Newborn
Women's Hospital School Of Medicine Zhejiang University
Observational
112
Hangzhou
2023-10-31
Recruiting
App and Body Fat Scale in the Management of Overweight Patients
NCT05866107Schizophrenia, Bipolar Disorder, Metabolic Syndrome, Overweight and Obesity
Capital Medical University
Not applicable
204
Beijing
2023-10-31
Recruiting
LeonaBio
Phase 3
600
Anhui, Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqicun
2023-10-31
Active, closed
Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus
NCT05749874PreDiabetes, Abdominal Obesity, Hypertension, Dyslipidemias
DrugBerberine
China National Center for Cardiovascular Diseases
Phase 4
2,024
Beijing
2023-10-31
Not yet open
Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL
NCT06062641Relapsed or Refractory B-cell Lymphoma
Ruijin Hospital
Phase 2
50
Shanghai
2023-10-30
Not yet open
Beijing Tiantan Hospital
Observational
20,000
Beijing
2023-10-30
Recruiting
Geneplus-Beijing Co. Ltd.
Observational
60
Beijing, Shanghai
2023-10-30
Recruiting
Xijing Hospital
Observational
3,000
Xi'an
2023-10-30
Recruiting
Xiangya Hospital of Central South University
Observational
64
Changsha
2023-10-30
Recruiting
Qianfoshan Hospital
Phase 2
51
Jinan
2023-10-30
Recruiting
Fu Wai Hospital, Beijing, China
Phase 4
252
Beijing
2023-10-30
Recruiting
First Affiliated Hospital Xi'an Jiaotong University
Observational
100
Xi'an
2023-10-30
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
95
Shanghai
2023-10-30
Recruiting
Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
NCT06190067Relapsed Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
DrugAzacitidine
Navy General Hospital, Beijing
Phase 2
40
Beijing
2023-10-30
Recruiting
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
NCT06030258Small Cell Lung Cancer Extensive Stage
DrugsIN10018·Etoposide·Tislelizumab·Carboplatin
InxMed (Shanghai) Co., Ltd.
Phase 1/2
120
Jinan, Tianjin, Zhengzhou
2023-10-30
Recruiting
NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia
NCT06125847Homozygous Familial Hypercholesterolemia
First Affiliated Hospital Xi'an Jiaotong University
Early Phase 1
21
Xi'an
2023-10-29
Active, closed
Dushu Lake Hospital Affiliated to Soochow University
Phase 1/2
13
Suzhou
2023-10-29
Recruiting
Preventive Effect of Probiotics in GDM
NCT06938464Gestational Diabetes Mellitus (GDM)
Women's Hospital School Of Medicine Zhejiang University
Not applicable
334
Hangzhou
2023-10-27
Recruiting
Allist Pharmaceuticals, Inc.
Phase 2
88
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-10-27
Active, closed
Vigonvita Life Sciences
Phase 1
82
Beijing
2023-10-27
Recruiting
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
NCT05978284Small Cell Lung Cancer, Neuroendocrine Carcinoma
DrugZG006
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
54
Zhengzhou
2023-10-27
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Hefei, Chongqing, Guangzhou, Shenzhen, Wuhan, Baotou, Nanjing, Nanchang
2023-10-27
Active, closed
Summit Therapeutics
Phase 3
1,600
Yangzhou, Tongzhou, Fuzhou, Lanzhou, Guangzhou, Nanning, Haikou, Shijiazhuang
2023-10-26
Recruiting
First Affiliated Hospital Xi'an Jiaotong University
Observational
40
Xi'an
2023-10-26
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
2,618
Hangzhou
2023-10-26
Recruiting
OriCell Therapeutics Co., Ltd.
Phase 1/2
83
Hangzhou, Beijing, Nanjing, Shanghai, Wuhan
2023-10-26
Recruiting
Study on c-Met Targeted PET/CT Imaging in NSCLC
NCT06911697PET/CT Imaging, NSCLC
Xilin Sun
Not applicable
88
Harbin
2023-10-26
Recruiting
Women's Hospital School Of Medicine Zhejiang University
Observational
100
Hangzhou
2023-10-26
Recruiting
Shanghai Yuyao Biotech Co., Ltd.
Phase 1
96
Shanghai
2023-10-26
Active, closed
Broadenbio Ltd., Co.
Phase 1
42
Beijing
2023-10-26
Recruiting
A Study of Chidamide With AZA in MRD Positive AML After Transplant
NCT06066905AML, Adult, Minimal Residual Disease
Guangdong Provincial People's Hospital
Not applicable
60
Guangzhou
2023-10-26
Recruiting
A Phase IIII Study of AL8326 in Small Cell Lung Cancer
NCT06247605Small Cell Lung Carcinoma
DrugAL8326
Advenchen Laboratories Nanjing Ltd.
Phase 3
243
Changchun
2023-10-26
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou
2023-10-25
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Observational
377
Shanghai
2023-10-25
Recruiting
Shanghai Kechow Pharma, Inc.
Phase 3
165
Beijing
2023-10-25
Active, closed
Peking University Cancer Hospital & Institute
Phase 2
20
Beijing
2023-10-25
Active, closed
Bristol-Myers Squibb
Phase 3
1,057
Hefei, Beijing, Lanzhou, Guangzhou, Shenzhen, Shenzhen Shi, Zhengzhou, Shijiazhuang
2023-10-25
Recruiting
Xiaofeng Chen
Phase 2
43
Nanjin
2023-10-25
Recruiting
Guangdong Provincial People's Hospital
Not applicable
120
Guangzhou
2023-10-25
Recruiting
The Correlation Between Ovarian Function and Serum Biomarkers
NCT06096766Premature Ovarian Insufficiency, Diminished Ovarian Reserve, Biomarker, Copper
Shi Yun
Observational
35
Beijing
2023-10-25
By invitation
T-DM1 Combined With CDK4/6 Inhibitor Ribociclib
NCT06481956HER2-positive Advanced Breast Cancer
DrugRibociclib
Zheng Yabing
Phase 2
40
Hangzhou
2023-10-25
Recruiting
Zhejiang Cancer Hospital
Phase 2
31
Hangzhou
2023-10-25
Recruiting
Lei ZHAO
Phase 2
40
Jinan
2023-10-25
Active, closed
Sinovac Biotech Co., Ltd
Phase 4
1,092
Shenyang
2023-10-24
Active, closed
AstraZeneca
Phase 3
895
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2023-10-24
Active, closed
Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia After Scoliosis Correction Surgery
NCT06062550Scoliosis Correction, Esketamine, Dexmedetomidine, Postoperative Analgesia
DrugEsketamine
Peking University First Hospital
Phase 4
312
Beijing
2023-10-24
Active, closed
Zhejiang Cancer Hospital
Phase 2
40
Hangzhou
2023-10-24
Recruiting
Beijing Tiantan Hospital
Observational
48
Beijing
2023-10-24
Recruiting
Effect of FPCA on Incidence of Emergency Delirium in Children After Surgery
NCT06092671Postoperative Complications, Child, Family, Emergence Delirium
Second Affiliated Hospital of Wenzhou Medical University
Not applicable
444
Wenzhou
2023-10-24
Recruiting
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
NCT06176729Diffuse Large B Cell Lymphoma
Yan Zhang, MD
Phase 2
30
Beijing
2023-10-24
Active, closed
Bristol-Myers Squibb
Phase 3
402
Hefei, Beijing, Chongqing, Xiamen, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-10-24
Recruiting
Xerostomia-optimised IMRT Versus Standard IMRT in NPC
NCT06282497Nasopharyngeal Carcinoma ,Xerostomia,Radiotherapy
Zhongshan People's Hospital, Guangdong, China
Not applicable
524
Zhongshan
2023-10-23
Active, closed
Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT06165380Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapies
Li Zhang
Phase 2
43
Wuhan
2023-10-23
Active, closed
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 2
114
Xiamen, Guangzhou, Zhengzhou, Wuhan, Yancheng, Shenyang, Qingdao, Shanghai
2023-10-23
Recruiting
Guangzhou 8th People's Hospital
Observational
60
Guangzhou
2023-10-23
Recruiting
Guangzhou 8th People's Hospital
Observational
400
Guangzhou
2023-10-23
Recruiting
The Affiliated Hospital of Xuzhou Medical University
Early Phase 1
14
Xuzhou
2023-10-22
Recruiting
Hoffmann-La Roche
Phase 3
182
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai
2023-10-22
Recruiting
The Affiliated Hospital of Xuzhou Medical University
Early Phase 1
14
Xuzhou
2023-10-22
Active, closed
Zhengzhou University
Phase 4
34
Zhengzhou
2023-10-21
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
342
Wuhu, Beijing, Xiamen, Guangzhou, Shenzhen, Guiyang, Haikou, Luoyang
2023-10-20
Not yet open
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC
NCT05993858Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
DrugCetuximab
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
33
Wuhan
2023-10-20
Recruiting
China Medical University Hospital
Not applicable
200
2023-10-20
Recruiting
Xuanwu Hospital, Beijing
Not applicable
80
Beijing
2023-10-20
Not yet open
Hangzhou Dinova EP Technology Co., Ltd
Not applicable
242
Nanjing
2023-10-20
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
54
Wuhan
2023-10-20
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
186
Shanghai
2023-10-20
Active, closed
A Study of BN104 in the Treatment of Acute Leukemia
NCT06052813ALL, Adult, AML, Adult, Acute Leukaemia, KMT2A Rearrangement
DrugBN104
Institut de Recherches Internationales Servier (I.R.I.S.)
Phase 1/2
66
Suzhou
2023-10-19
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
180
Beijing, Fuzhou, Zhengzhou, Changsha, Nanjing, Nanchang, Changchun, Jinan
2023-10-19
Active, closed
China-Japan Friendship Hospital
Observational
94
Beijing
2023-10-19
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 3
222
Fuzhou, Xiamen, Nanning, Nanjin, Suzhou, Shanghai, Kunming
2023-10-19
Not yet open
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
NCT06063070Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer, Primary Peritoneal Cancer
DrugsFluzoparib·Bevacizumab
Sun Yat-sen University
Phase 2
44
Guangzhou
2023-10-18
Recruiting
Pan Xiangbin
Not applicable
120
Beijing
2023-10-18
Recruiting
An Imaging Study of Polyvascular Disease
NCT06016608Polyvascular Disease
Harbin Medical University
Observational
1,100
Harbin
2023-10-18
Recruiting
Huashan Hospital
Phase 2
50
Shanghai
2023-10-18
Recruiting
Abbisko Therapeutics Co, Ltd
Phase 2
82
Shanghai, Chengdu, Ha’erbin, Wuhan
2023-10-17
Recruiting
De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCC
NCT06572514Locally Advanced Head and Neck Squamous Cell Carcinoma
Ruijin Hospital
Phase 1/2
20
Shanghai
2023-10-17
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
63
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yongzhou, Shenzhen, Xi’an
2023-10-17
Recruiting
Neuracle Medical Technology(Shanghai) Co.,Ltd.
Not applicable
9
Beijing, Shanghai
2023-10-17
By invitation
Identification and Functional Study of Novel Biomarkers for Cardiovascular Diseases
NCT06690684Angiocardiography, Heart Failure, Ischemic Heart Disease, Acute Myocardial Infarction (AMI)
Ya-Wei Xu
Observational
300
Shanghai
2023-10-17
Active, closed
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
72
Shanghai
2023-10-17
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Not applicable
200
Nanjing
2023-10-17
Active, closed
Akeso
Phase 1/2
216
Harbin
2023-10-16
Recruiting
Shanghai Mental Health Center
Not applicable
18
Shanghai
2023-10-16
Recruiting
Beijing Pearl Biotechnology Limited Liability Company
Phase 3
136
Guangzhou
2023-10-16
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
120
Beijing
2023-10-16
Active, closed
Otsuka Beijing Research Institute
Phase 1/2
72
Hangzhou
2023-10-16
Not yet open
The Second Affiliated Hospital of Shandong First Medical University
Phase 2
50
Tai’an
2023-10-15
Recruiting
Cohort of Twin Pregnancy and the Offspring
NCT05727085Twin Pregnancy
Fudan University
Observational
1,000
Shanghai
2023-10-15
Not yet open
GrandPharma (China) Co., Ltd.
Observational
200
Hangzhou
2023-10-15
Active, closed
China National Center for Cardiovascular Diseases
Not applicable
2,700
Beijing
2023-10-15
Recruiting
Preoperative Serum FGF19 in the Prognosis of Biliary Atresia
NCT05848310Biliary Atresia, Prognosis
Children's Hospital of Fudan University
Observational
200
Shanghai
2023-10-15
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
DrugObrixtamig
Boehringer Ingelheim
Phase 2
204
Chengdu, Hangzhou, Jinan, Nanchang, Shanghai
2023-10-13
Active, closed
Shandong Boan Biotechnology Co., Ltd
Phase 3
510
Guangzhou
2023-10-12
By invitation
AQTIS Medical B.V.
Observational
374
Guangzhou
2023-10-12
Recruiting
China Medical University Hospital
Phase 2
90
2023-10-12
Active, closed
Janssen Research & Development, LLC
Phase 3
684
Beijing, Bengbu, Chengde, Chengdu, Jiaxing, Jinan, Nanchang, Nanyang
2023-10-12
Recruiting
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
132
Shanghai
2023-10-11
Recruiting
Chinese PLA General Hospital
Phase 1/2
30
Beijing
2023-10-11
Recruiting
Hangzhou Broncus Medical Co., Ltd.
Not applicable
110
Shanghai
2023-10-11
Recruiting
AbbVie
Phase 3
1,500
Beijing, Chongqing, Guangzhou, Shenzhen, Wuhan, Nanchang, Changchun, Xi'an
2023-10-11
Active, closed
Acute Health Effects of Low Temperature Exposure
NCT06076629Cardiovascular System, Respiratory System, Cognitive Function
Fudan University
Not applicable
50
Shanghai
2023-10-10
Recruiting
The Second Affiliated Hospital of Chongqing Medical University
Phase 2
1,200
Chongqing
2023-10-10
Recruiting
Sanofi
Phase 3
180
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wuxi
2023-10-10
Recruiting
BioRay Pharmaceutical Co., Ltd.
Phase 1
164
Guangzhou
2023-10-10
Recruiting
The Second Affiliated Hospital of Chongqing Medical University
Phase 2
120
Chongqing
2023-10-10
Recruiting
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B)
NCT07845058Chronic Hepatitis B, Anti-PD-1 Antibody, Anti-PD-L1 Antibody, Peg-IFNα
DrugPeg-IFNα
The Second Affiliated Hospital of Chongqing Medical University
Phase 2
1,200
Chongqing
2023-10-10
Recruiting
The Second Affiliated Hospital of Chongqing Medical University
Phase 2
120
Chongqing
2023-10-10
Recruiting
Women's Hospital School Of Medicine Zhejiang University
Observational
1,080
Hangzhou
2023-10-10
Recruiting
Peking Union Medical College
Not applicable
150
Beijing
2023-10-10
Recruiting
Fujian Provincial Hospital
Observational
30
Fuzhou
2023-10-09
Recruiting
Sun Yat-sen University
Phase 3
504
Guangzhou
2023-10-09
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Hefei, Beijing, Chongqing, Foshan, Guangzhou, Huizhou, Jiangmen, Shenzhen
2023-10-09
Recruiting
Tang-Du Hospital
Phase 2
20
Xi'an
2023-10-09
Recruiting
BioSyngen Pte Ltd
Early Phase 1
14
Zhengzhou
2023-10-09
Active, closed
The Hong Kong Polytechnic University
Not applicable
170
Hong Kong
2023-10-08
Recruiting
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
12
Shanghai
2023-10-08
Active, closed
Guangdong Provincial People's Hospital
Not applicable
126
Guangzhou
2023-10-08
Recruiting
CARsgen Therapeutics Co., Ltd.
Phase 1
30
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guanzhou, Hangzhou, Shanghai
2023-10-08
Not yet open
Henan Provincial People's Hospital
Phase 2
30
Zhengzhou
2023-10-05
Active, closed
AstraZeneca
Phase 3
5,511
Baoding, Beijing, Bengbu, Binzhou, Cangzhou, Changchun, Changsha, Chengdu
2023-10-05
Recruiting
China Medical University Hospital
Phase 2
90
2023-10-04
Recruiting
ML Models Predicting Cycloplegic Refractive Error Based on Non-Cycloplegic Parameters in Myopic Adults
NCT07690813Refractive Errors, Cycloplegic Refraction, Accommodation
Second Affiliated Hospital of Nanchang University
Observational
2,500
Jiangxi
2023-10-03
Recruiting
Pfizer
Phase 4
80
Beijing, Guangzhou, Jinan, Hangzhou
2023-10-03
Rows per page Showing 14501–15000 of 19187
Previous 28 29 30 31 32 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 8 November 2026. https://priyalifescience.com/clinical-trials-china?page=30

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

How many clinical trials are recruiting in China?

11,790 of the 19,187 studies in this register are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 3,998 have not yet opened recruitment, 2,715 are active but closed to new participants, and 684 are enrolling by invitation only. Eligibility for any study is decided by its study team.

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by condition

Breast Cancer (423) Advanced Solid Tumors (187) Colorectal Cancer (179) Gastric Cancer (175) Hepatocellular Carcinoma (154) Advanced Solid Tumor (153) Non-Small Cell Lung Cancer (145) Solid Tumor (142) Acute Ischemic Stroke (140) Lung Cancer (135) Non-small Cell Lung Cancer (132) Pancreatic Cancer (131) Multiple Myeloma (128) Coronary Artery Disease (122) Prostate Cancer (110)
→

Browse trials by site location

Beijing (5576) Shanghai (3879) Guangzhou (3345) Hangzhou (1819) Wuhan (1343) Chengdu (1307) Nanjing (1211) Changsha (1154) Chongqing (1078) Fuzhou (1040) Tianjin (934) Zhengzhou (931) Hefei (896) Jinan (783) Changchun (639)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.